FDA Approved: DEPAKOTE — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved AbbVie's supplemental application for DEPAKOTE (divalproex sodium), updating regulatory labeling as part of the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy
• Migraine

Drugs mentioned

• DEPAKOTE (DIVALPROEX SODIUM)

Snippet

SUPPL AP for DEPAKOTE (DIVALPROEX SODIUM)